afala

08/01/2009 - "The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. "
05/01/2009 - "Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination. "
09/01/2012 - "The double-blind, placebo-controlled, randomized clinical trial involving 94 patients has evaluated the efficacy and safety of domestic preparation afala in patients with symptoms of I-II stages benign prostatic hyperplasia (BPH). "
08/01/2009 - "Experience of long-term afala treatment in benign prostatic hyperplasia."
08/01/2009 - "Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia."

08/01/2009 - "The use of afala in complex treatment of patients with chronic prostatitis improves the efficiency of therapy and prolongs its positive results. "
08/01/2009 - "Afala is indicated for patients with stages II and IIIa chronic prostatitis from the first day of therapy."
08/01/2009 - "Efficiency of afala in complex therapy of patients with chronic prostatitis."
08/01/2009 - "The efficiency of afala in the therapy of chronic abacterial prostatitis was demonstrated. "
08/01/2009 - "Clinical use of afala in the therapy of chronic prostatitis."

04/01/2014 - "In the hormone-dependent prostate inflammation model induced by implantation of slow-releasing pellets (50 mg testosterone and 5 mg estradiol) to Noble male rats, intragastric administration of Afala at a dose of 7.5 ml/kg for 18 weeks reduced the number of inflamed prostatic acini. "
04/01/2014 - "Effects of afala and antiestrogen ICI 182,780 in the model of hormone-dependent prostate inflammation."

04/01/2014 - "As differentiated from the antiestrogen ICI 182,780, afala did not induce body weight gain and decrease in pituitary weight in experimental animals in comparison with the control group."